Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2023-08-31 Capital/Financing Update
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
WRAP Retail Offer for up to £0.5m
Capital/Financing Update Classification · 1% confidence The document is an official announcement released via RNS (Regulatory News Service), indicated by the 'RNS Number' header and the date stamp. The content explicitly announces a 'WRAP Retail Offer' to raise capital (£500,000) through the issue of new ordinary shares, alongside details of a separate subscription to raise £1.35 million. This clearly falls under the category of company fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). Although it is an RNS announcement, the core subject matter is the financing activity itself, making CAP more specific than the general RNS fallback.
2023-08-31 English
Subscription to raise £1.35m; Sharing Agr, RPT
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Immupharma PLC, identified by the RNS Number (8695K) and the date (31 August 2023). The content details a fundraising activity involving subscriptions, a Sharing Agreement with a major shareholder (Lanstead), and a proposed Retail Offer. This clearly falls under the category of corporate financing and capital structure changes. The key terms are 'Subscriptions to raise £1.35 million', 'issue of new ordinary shares', and 'Retail Offer'. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing transaction itself.
2023-08-31 English
Interim results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS' for the six months ended 30 June 2023. It contains detailed financial statements, including a Consolidated Income Statement, and provides a comprehensive management review of business operations, clinical trial progress, and corporate updates. Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-31 English
Extension of warrants in Incanthera plc
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and is dated '21 August 2023'. It announces an 'Extension of Warrants' between Immupharma PLC and Incanthera plc. The text explicitly states, 'This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation...' and concludes with contact information for RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. This structure is characteristic of a general regulatory news service announcement, which fits the definition of 'Regulatory Filings' (RNS) as a miscellaneous regulatory announcement, especially since the content is a specific corporate action update rather than a full financial report (like 10-K or IR) or a management/board change (MANG). Given the context of RNS distribution and the nature of the announcement, RNS is the most appropriate classification.
2023-08-21 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is an official announcement released via RNS (Regulatory News Service) on August 11, 2023. The headline explicitly states 'BOARD STRENGTHENED AHEAD OF NEXT PHASE OF COMPANY PROGRESSION' and the text details the appointment of Dr. Laurence Reilly and Dr. Sébastien Goudreau, and the stepping down of Dr. Sanjeev Pandya. This content directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter overrides the general 'RNS' fallback category.
2023-08-11 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states: '2023 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED'. It then provides a detailed table showing the voting results (For, Against, Withheld) for each resolution presented at the AGM. This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core content is the *result* of the vote, not the presentation materials (AGM-R) or the proxy solicitation (PSI). The presence of the RNS Number and the closing statement about RNS confirms it is a regulatory announcement, but DVA is the most specific category.
2023-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.